BridgeBio Pharma (BBIO) Cost of Revenue (2021 - 2026)

BridgeBio Pharma has reported Cost of Revenue for 6 years, with the latest figure at $9.9 million in Q1 2026.

• Quarterly Cost of Revenue rose 276.62% year-over-year to $9.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.3 million (up 377.48% YoY) and the FY2025 annual result came in at $21.0 million, up 440.54% from the prior year.
• Cost of Revenue rose to $9.9 million in Q1 2026 per BBIO's latest filing, from $8.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $9.9 million in Q1 2026 and troughed at $598000.0 in Q3 2023.
• A 5-year average of $2.4 million and a median of $700000.0 in 2022 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue tumbled 58.28% in 2022, then soared 997.49% in 2025.
• Over 5 years, Cost of Revenue stood at $647000.0 in 2022, then dropped by 7.57% to $598000.0 in 2023, then soared by 248.49% to $2.1 million in 2024, then jumped by 289.01% to $8.1 million in 2025, then climbed by 22.6% to $9.9 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $9.9 million, $8.1 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.